Compound Directory
A reviewed compound profile linking technical facts, evidence summaries, limitations, studies, trials, COAs, and related products.
Clickable primary records and approved journal metadata.
pubmed
Jian Wang, Junxiang Gu, Fujuan Ma, Yi Wei, Pan Wang, Shanming Yang, Xianxia Yan, Yifan Xiao, Keke Xing, Anxin Lou, Liru Zheng, Tingting Cao, Dayu Zhu, Jinlian Li, Luoying Zhang, Yunqing Li, Tao Chen · Research (Washington, D.C.) · 2024
Preclinical animal study · Human participants; verify the population in the source
Open source recordpubmed
Yueqin Feng, Xiaowen Jiang, Wenwu Liu, Hongyuan Lu · European journal of medicinal chemistry · 2023
Preclinical animal study · Animal model; verify the species in the source
Open source recordpubmed
Gabriella Gobbi, Stefano Comai · Frontiers in endocrinology · 2024
Preclinical animal study · Animal model; verify the species in the source
Open source recordpubmed
Min Chen, Erika Cecon, Angeliki Karamitri, Wenwen Gao, Romain Gerbier, Raise Ahmad, Ralf Jockers · Journal of pineal research · 2021
Preclinical animal study · Animal model; verify the species in the source
Open source recordpubmed
Crystell G Guzmán-Priego, Itzel I Ramos-Rodríguez, Juan M Pizaña-Encarnación, Ana M Islas-Espinoza, María J Escoto-Rosales, Diana K Morales-Galindo, Myrna Déciga-Campos, Erick J Rodríguez-Palma, Vinicio Granados-Soto · European journal of pharmacology · 2025
Preclinical animal study · Animal model; verify the species in the source
Open source recordpubmed
W Liu, H Jiang, X Liu, S Hu, H Li, Y Feng, J Ke, X Long · Journal of dental research · 2022
Preclinical animal study · Human participants; verify the population in the source
Open source recordOnly approved public COAs matched to this product, strength, lot, and batch are shown.
historical · Lot 8260410
2604270105 · 2026-04-22
NCT04073433 · WITHDRAWN
The goal of this clinical trial is to study MDMA-assisted therapy in healthy volunteers and provide training of therapists. The main question it aims to answer is: Does MDMA-assisted therapy result in personal and professional benefits? Participants will have a non-drug preparatory session prior to each experimental session and an integrative session after each experimental session.
Outcomes: Change from Baseline in Self Compassion Scale (SCS) total score
NCT01180855 · UNKNOWN
The specific aims of the proposed study are to compare the sleep, daytime functioning, and circadian phase effects of ROZEREMTM (ramelteon/TAK-375) a selective MT1/MT2 melatonin receptor agonist in humans alone and in combination with multi-component behavior therapy (MCBT) in patients with chronic insomnia.
Outcomes: Sleep Onset Latency · Dim Light Melatonin Onset
NCT00391755 · TERMINATED
To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor agonist used for insomnia, as a migraine prophylactic agent.
Outcomes: Statistically significant reduction in migraine headaches in the Rozerem treated group. · Improvement in sleep satisfaction in the Rozerem treated group.
NCT06489327 · RECRUITING
Preoperative anxiety is a common issue in pediatric anesthesia. Children often experience anxiety and uneasiness due to uncertain outcomes. Surgery and anesthesia are among the most traumatic experiences for children, often considered anxiety-inducing medical treatments. Because they lack control over their environment and circumstances, children undergoing medical procedures typically experience significant unease or anxiety. Several studies have reported that 50%-80% of children experience preoperative anxiety. In order to reduce kids anxiety intensity, several measures are utilized. These strategies are either pharmacological, psychological, or behavioural. Benzodiazepines are popular drugs that can reduce anxiety in children. The most used one in premedication is midazolam. It is a rapid-acting benzodiazepine that has a short elimination half-life. It has sedative, anxiolytic, hypnotic, and anterograde amnesic effects. Midazolam, on the other hand, might have a number of negative consequences, including paradoxical reactions, interactions with opioids, excessive sedation, disorientation, and reduced psychomotor performance. Melatonin enhances anti-nociceptive effects, most prominently through the modulation of MT1/MT2 receptors in the brain and spinal cord. In addition, it has been demonstrated that melatonin can interact with additional receptors, including those in the GABAergic system, the nitric oxide (NO)arginine route, the N-Methyl-D-aspartate (NMDA) system, and the dopaminergic system, to produce anti-nociceptive and anti-allodynic effects.
Outcomes: preoperative anxiety · preoperative sedation
NCT04959825 · COMPLETED
Melatonin is a hormone that the pineal gland in the brain produces. Melatonin fulfills many functions in the body but it is mostly known for maintaining a circadian rhythm that is governed by the central circadian pacemaker (biological clock) in the suprachiasmatic nuclei in the hypothalamus. Melatonin works by attaching to receptors or nerve endings in the suprachiasmatic nucleus (SCN) in the hypothalamus. It binds to melatonin receptor 1 and melatonin receptor 2, commonly referred to as MT1 and MT2. People can take it as a natural or synthetic supplement to promote restful sleep. Melatonin showed promise for preventing shifts in sleep and wake times in people with jetlag and improving sleep in people with insomnia. It can also be used for headaches, cancer, and Alzheimer's disease. Melatonin can be used as an analgesic, sedative, and hypnotic drug that can distinguish it as an attractive alternative premedicant
Outcomes: Inhaled isoflurane requirement (volume%) to maintain entropy readings 40-60 · Total morphine consumption over 24 hours postoperative · Total intraoperative fentanyl consumption
